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Abstract Dietary methyl donors might influence DNA
methylation during carcinogenesis of colorectal cancer
(CRC). Among 609 CRC cases and 1,663 subcohort
members of the Netherlands Cohort Study on diet and
cancer (n = 120,852), we estimated CRC risk according to
methyl donor intake across genotypes of folate metabo-
lizing enzymes and methyltransferases.
Although diet–gene interactions were not statistically
significant, methionine intake was inversely associated
with CRC among subjects having both common rs2424913
and rs406193 DNMT3B C [ T genotypes (highest versus
lowest tertile: RR = 0.44; ptrend = 0.05). Likewise, vita-
min B2 was modestly inversely associated among indi-
viduals with the MTHFR c.665CC (rs1801133) genotype
(RR = 0.66; ptrend = 0.08), but with a significant reduced
risk when B 1 rare allele occurred in the combination of
folate metabolizing enzymes MTHFR, MTRR and MTR
(RR = 0.30; ptrend = 0.005). Folate or vitamin B6 were
neither inversely associated with CRC nor was methyl
donor intake associated with the CpG island methylator
phenotype (CIMP).
Despite the absence of heterogeneity across genotypes,
might an effect of methyl donors on CRC be more pro-
nounced among individuals carrying common variants of
folate metabolizing enzymes or DNA methyltransferases.
Combining genotypes may assist to reveal diet associations
with CRC, possibly because rare variants of related genes
may collectively affect specific metabolic pathways or
enzymatic functions.
Keywords Methyl donors  Diet–gene interactions 
Promoter hypermethylation  CRC
Introduction
Hypermethylation of CpG islands in gene promoters is an
important epigenetic alteration involved in carcinogenesis
[1]. In colorectal cancer (CRC), the CpG island methylator
phenotype (CIMP) is characterized by frequent promoter
CpG island hypermethylation [2]. However, little is known
about potential determinants of this type of aberrant DNA
methylation in CRC.
Folate and methionine are dietary methyl group donors
that may be hypothesized to influence DNA methylation,
whereas vitamins B2 and B6 potentially modulate the
bioavailability of methyl groups [3, 4]. Low folate status or
intake was suggested to decrease genomic methylation
[5–8], while folate supplementation resulted in increased
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global DNA methylation in the colonic mucosa [9]. Ade-
quate methyl donor intake possibly also prevents aberrant
CpG island promoter hypermethylation. In this respect, a
weak inverse association with gene promoter hyperme-
thylation was suggested [10], although methyl donor intake
and alcohol consumption, which may reduce the bioavail-
ability of folate, were not associated with CIMP in CRC
[11]. Conversely, folate supplementation was suggested to
increase promoter hypermethylation of multiple genes in
colorectal mucosa [12], and circulating folate concentra-
tion was associated with increased gene promoter hyper-
methylation in colorectal tumors [13]. In addition, high
vitamin B6 intake may be associated with increased MutL
homologue 1 (MLH1) promoter methylation in CRC [14].
Apparently, the precise effect of methyl group bioavail-
ability on gene promoter hypermethylation is still unclear
and should be investigated further.
A potential effect of methyl donor intake on DNA meth-
ylation may be modified by polymorphisms in folate
metabolizing enzymes. For example, the catalytic activity of
the methylene tetrahydrofolate reductase (MTHFR) enzyme
may be reduced in individuals carrying rare variants of the
MTHFR c.665C [ T (rs1801133) and c.1286A [ C
(rs1801131) polymorphisms [15, 16], which were also
associated with the CIMP phenotype in colorectal cancer
[17–19]. We previously observed inverse associations
between methionine synthase (MTR) c.2756A[G (rs1805087)
and CIMP, and between methionine synthase reductase (MTRR)
c.66A[G (rs1801394) with MLH1 hypermethylation [20].
Other enzymes involved in epigenetic regulation of gene
expression are DNA methyltransferases (DNMTs) and histone
methyltransferases (HMTs). However, whether an influence of
methyl donor intake is modified by polymorphisms in such
epigenetic regulators has not previously been studied in relation
to CRC.
Here, we aimed to investigate associations between
dietary folate, methionine, vitamins B2 and B6 with overall
CRC, and risk of CRCs harboring CIMP, accounting for
the occurrence of any, or combinations of rare variants of
folate metabolizing enzymes MTHFR, MTR and MTRR, the
DNA methyltransferase DNMT3B, and histone methyl-
transferases Euchromatin histone methyltransferase 1
(EHMT1), Euchromatin histone methyltransferase 2
(EHMT2) and PR domain zinc finger protein 2 (PRDM2) in
the Netherlands Cohort Study on diet and cancer.
Methods
Study population
The participants of this study were incident CRC patients
from the Netherlands Cohort Study on diet and cancer
(NLCS), which has been described in detail elsewhere [21].
Briefly, this prospective cohort study was initiated in
September 1986 and includes 58,279 men and 62,573
women aged 55–69 years and free of disease at baseline.
The cohort is followed for cancer occurrence by annual
record linkage to the Netherlands Cancer Registry (NCR)
and to the Pathologisch Anatomisch Landelijk Geauto-
matiseerd Archief (PALGA), a nationwide network and
registry of histopathology and cytopathology reports [22,
23]. A subcohort of 5,000 subjects was randomly selected
after baseline exposure measurement, to estimate accu-
mulation of person-time in the cohort through biennial
follow-up of vital status. Cases with prevalent cancer other
than non-melanoma skin cancer were excluded from this
subcohort, which left 4,774 men and women eligible for
analysis.
Food frequency questionnaire
At baseline, participants filled out a self-administered, 150-
item semi-quantitative food frequency questionnaire
(FFQ), which concentrated on habitual consumption of
food and beverages during the year preceding the start of
the study, and also contained questions about age, sex,
body weight and length, smoking status and family history
of CRC. Daily mean nutrient intakes were calculated as the
cumulated product of the frequencies and portion sizes of
all food items and their tabulated nutrient contents from the
Dutch Food Composition Table (NEVO table, 1986) [24].
The questionnaire was validated through comparison with
a 9-day diet record [25]. Reproducibility and stability of
dietary habits were determined by five annually repeated
measurements [26]. In order to minimize observer bias in
coding and interpretation of the data, questionnaire data
were key-entered twice for all incident cases in the cohort
and for all subcohort members in a blinded manner with
respect to case/subcohort status.
Folate data were derived from a validated liquid chro-
matography trienzyme method [27] used to analyze the 125
most important Dutch foods contributing to folate intake
[28]. Dietary supplement data were also obtained via the
food frequency questionnaire. However, the use of B-vita-
min supplements was low (7%) and folic acid was generally
not included in these supplements in the Netherlands in the
late 1980s. Therefore, folic acid supplement use most likely
plays a very minor role in our study population, and sup-
plement use was not further accounted for in the analyses.
Sample collection
Subcohort members still alive in December 2000
(n = 3,579) were contacted and asked to collect mouth
swabs, of whom 1,929 (54%) responded and returned the
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mouth swab with informed consent. In total, DNA could
successfully be isolated of 1,829 subcohort members who
also had complete follow-up information [20].
Tumor material of the CRC patients was collected after
approval by the ethical review boards of Maastricht Uni-
versity, the NCR and PALGA. During a follow-up period
of 7.3 years after baseline, 734 incident CRC patients were
identified who had an available PALGA report of the lesion
as well as a sufficient amount of isolated DNA needed for
molecular analyses.
Genotyping analyses
MTHFR (rs1801133 and rs1801131), MTR (rs1805087),
MTRR (rs1801394), DNMT3B (rs2424913 and rs406193),
EHMT1 (rs4634736), EHMT2 (rs535586) and PRDM2
(rs2235515) genotypes were determined using multiplex
polymerase chain reaction (PCR) amplification and single
base extension (SBE) reactions as described previously [20,
29]. Genotype data were validated by sequencing of frag-
ments containing specific SNPs, which were similar to the
main results for all but one (99.6%) of the 9 SNPs within a
subset of 30 samples [20]. Reproducibility of the analysis
was established among 93 samples, and we observed that the
analyses could be reproduced in 99.5% of these cases [20]. In
total, genotyping analyses were successful from 1,736 sub-
cohort members and 659 CRC patients.
Promoter methylation analyses
The CpG island methylator phenotype (CIMP) was defined
by promoter hypermethylation of at least 3 out of 5 methyl-
ation markers (CACNA1G, IGF2, NEUROG1, RUNX3, and
SOCS1), as suggested by Weisenberger et al. [2]. Hyper-
methylation of the CpG islands of these five CIMP markers
and of the MLH1 gene was determined by Methylation
Specific PCR (MSP) [30] and described in detail by de Vogel
et al [20]. The MSP analyses were successful of 81, 79, 79,
90, 83, and 93% out of the 734 patients for CACNA1G, IGF2,
NEUROG1, RUNX3, SOCS1, and MLH1, respectively.
Microsatellite instability
MSI was determined by a pentaplex PCR, using the MSI
markers BAT-26, BAT-25, NR-21, NR-22 and NR-24, as
described in detail by Suraweera et al. [31]. MSI analyses
were successful on 662 (90%) out of the 734 available
samples.
Statistical analyses
Cox proportional hazards regression models were used to
estimate multivariate-adjusted incidence rate ratios (RR)
and corresponding 95% confidence intervals (CI) over ter-
tiles of dietary folate, methionine, vitamins B2 and B6,
using the lowest tertiles as reference. Tests for dose
response trends over the tertiles of intake were estimated by
fitting the ordinal exposure variables as continuous vari-
ables and evaluated using the Wald test. Standard errors of
the RR were estimated using the robust Huber-White
sandwich estimator to account for additional variance
introduced by sampling from the cohort [32]. The propor-
tional hazards assumption was tested using the scaled
Schoenfeld residuals [33] and by fitting the main determi-
nants as time-dependent variables. The dietary variables
were adjusted for total energy intake by calculating nutrient
residuals from the regression of nutrient intake on total
energy intake, as described by Willett et al. [34]. The
analyses were stratified according to genetic status of
individuals, i.e. among those homozygous to common
genetic variants and among subjects carrying rare alleles.
Interactions were tested between dietary folate, methionine,
vitamins B2 and B6, and each of the genetic variants.
Associations between dietary factors and CRC were also
estimated for combinations of genotypes per functional
group (i.e. based on the number of rare alleles in any of the
folate metabolizing enzymes MTHFR, MTR and MTRR, in
the DNA methyltransferase DNMT3B, or in any of the
histone methyltransferases EHMT1, EHMT2 and PRDM2.
To investigate whether dietary methyl donors have an
effect on promoter hypermethylation in CRC, associations of
folate, methionine, vitamins B2, and B6 with the CIMP phe-
notype were estimated. The associations with MLH1 hyper-
methylation and MSI were reported previously [14].
Furthermore, it was investigated whether the associations with
MLH1 hypermethylation, MSI, or CIMP would be modified
by genetic status, by estimating the associations with meth-
ylation endpoints within genotypes of folate metabolizing
enzymes, DNMT3B and histone methyltransferases.
All models included the co-variates dietary folate,
methionine, vitamin B2 and B6 and were additionally
adjusted for age, sex, family history of CRC, smoking
status, body mass index (BMI), alcohol consumption, and
energy intake. After excluding subjects with missing
information on these covariates or subjects who did not
completely filled out the questionnaire, 1,663 subcohort
members and 609 CRC cases remained for statistical
analyses. All analyses were performed with the Stata sta-
tistical software package (version 10).
Results
CRC risk was estimated over tertiles of folate intake,
methionine, vitamins B2 and B6, among subjects homozy-
gous for common alleles and among carriers of rare alleles.
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Folate or methionine intakes were not associated with CRC
within either common homozygotes or within heterozygotes
and rare homozygotes of any of the genotypes (Table 1).
However, we observed a non-significant inverse association
between vitamin B2 intake and CRC risk among subjects
with the MTHFR c.665CC (rs1801133) common genotype
(RR for the highest versus the lowest tertile of intake =
0.66, ptrend = 0.08, Table 2), and an inverse association
among subjects with the common GG genotype of PRDM2
G [ A (rs2235515, RR = 0.67, ptrend = 0.05). In addition,
vitamin B2 was associated with reduced CRC risk in indi-
viduals carrying the variant allele of DNMT3B C [
T (rs2424913, RR = 0.69, ptrend = 0.05). Conversely, sub-
jects in the third tertile of vitamin B6 intake were at increased
CRC risk when they carried the rare allele of DNMT3B
C [ T (rs406193, RR = 1.90, ptrend = 0.04), or the com-
mon allele of PRDM2 G [ A (rs2235515, RR = 1.49,
ptrend = 0.03). However, interactions between these dietary
factors and genotypes were not statistically significant.
We also investigated the associations between methyl
donor intake and CRC risk according to the number of rare
alleles within each functional group (i.e. folate metabolizing
enzymes, DNMT3B and histone methyltransferases). It
appeared that methionine was inversely associated with
CRC if subjects were homozygous to both of the common
variants of the DNMT3B rs2424913 and rs406193 C [
T SNPs (RR = 0.44, ptrend = 0.05, Pinteraction = 0.07,
Table 3). Moreover, relatively high vitamin B2 intake was
associated with reduced CRC risk in subjects carrying less
than one rare variant of folate metabolizing enzymes
(RR = 0.30, ptrend = 0.005, Pinteraction = 0.36, Table 4).
No dietary associations were observed according to the
number of rare alleles in the studied histone methyltrans-
ferases (Table 5).
With respect to CpG island promoter hypermethylation,
we observed no overall associations between folate, methi-
onine, vitamins B2 or B6 with CIMP (Table 6). Moreover,
there were no clear associations between methyl donor
intake and CIMP, MLH1 hypermethylation or MSI when
accounting for genetic status of individuals (data not shown).
Discussion
In the current prospective case-cohort study, we observed
no clear associations between dietary folate and vitamin B6
with CRC risk when accounting for genetic variants of
folate metabolizing enzymes, DNA methyltransferases, or
histone methyltransferases. However, relatively high
methionine intake may protect against CRC if enzymatic
activity of DNMT3B is not affected by two C [ T SNPs in
its encoding gene. In addition, subjects with high vitamin
B2 intake may be at reduced CRC risk in combination withT
a
b
le
1
co
n
ti
n
u
ed
F
o
la
te

M
et
h
io
n
in
e
G
en
e
an
d
S
N
P
(r
s
n
u
m
b
er
,
M
A
F
)*
T
er
ti
le
C
o
m
m
o
n
h
o
m
o
zy
g
o
te
s
H
et
er
o
zy
g
o
te
s
an
d
ra
re
h
o
m
o
zy
g
o
te
s
C
o
m
m
o
n
h
o
m
o
zy
g
o
te
s
H
et
er
o
zy
g
o
te
s
an
d
ra
re
h
o
m
o
zy
g
o
te
s
o
f
in
ta
k
e
n
§
R
R
(9
5
%
C
I)
n
R
R
(9
5
%
C
I)
p
in
te
ra
c
ti
o
n
n
R
R
(9
5
%
C
I)
n
R
R
(9
5
%
C
I)
p
in
te
ra
c
ti
o
n
P
R
D
M
2
G
[
A
(r
s2
2
3
5
5
1
5
,
0
.2
3
)
1
1
1
6
R
ef
.
1
0
6
R
ef
.
0
.9
8
1
2
0
R
ef
.
8
5
R
ef
.
0
.1
9
2
9
3
0
.6
7
(0
.4
6
–
0
.9
6
)
6
5
0
.6
1
(0
.3
9
–
0
.9
6
)
1
0
7
0
.9
5
(0
.6
6
–
1
.3
5
)
9
0
1
.2
9
(0
.8
3
–
2
.0
1
)
3
1
2
1
0
.9
5
(0
.6
5
–
1
.3
9
)
9
5
0
.9
3
(0
.6
1
–
1
.4
3
)
1
0
3
0
.9
7
(0
.6
5
–
1
.4
3
)
9
1
1
.0
2
(0
.6
4
–
1
.6
4
)
p
tr
e
n
d
0
.8
1
0
.8
6
0
.6
9
0
.9
1
*
S
N
P
:
S
in
g
le
N
u
cl
eo
ti
d
e
P
o
ly
m
o
rp
h
is
m
,
M
A
F
:
M
in
o
r
A
ll
el
e
F
re
q
u
en
cy
am
o
n
g
su
b
co
h
o
rt
m
em
b
er
s

A
m
o
n
g
su
b
co
h
o
rt
m
em
b
er
s
w
it
h
in
te
rt
il
es
:
m
ed
ia
n
fo
la
te
in
ta
k
e:
1
6
2
,
2
0
0
an
d
2
5
5
l
g
/d
ay
;
ac
cu
m
u
la
te
d
ti
m
e
at
ri
sk
:
4
1
3
1
,
4
0
9
1
an
d
4
0
9
3
p
er
so
n
y
ea
rs

A
m
o
n
g
su
b
co
h
o
rt
m
em
b
er
s
w
it
h
in
te
rt
il
es
:
m
ed
ia
n
m
et
h
io
n
in
e
in
ta
k
e:
1
3
1
6
,
1
5
8
3
an
d
1
8
8
1
m
g
/d
ay
;
ac
cu
m
u
la
te
d
ti
m
e
at
ri
sk
:
4
1
1
0
,
4
1
0
5
an
d
4
1
0
0
p
er
so
n
y
ea
rs
§
N
u
m
b
er
o
f
co
lo
re
ct
al
ca
n
ce
r
ca
se
s
}
R
R
s
b
as
ed
o
n
a
m
o
d
el
co
n
ta
in
in
g
th
e
v
ar
ia
b
le
s
fo
la
te
,
m
et
h
io
n
in
e,
v
it
am
in
B
2
,
v
it
am
in
B
6
,
an
d
fu
rt
h
er
ad
ju
st
ed
fo
r
ag
e,
se
x
,
fa
m
il
y
h
is
to
ry
o
f
co
lo
re
ct
al
ca
n
ce
r,
b
o
d
y
m
as
s
in
d
ex
,
sm
o
k
in
g
st
at
u
s,
al
co
h
o
l
co
n
su
m
p
ti
o
n
an
d
to
ta
l
en
er
g
y
in
ta
k
e
*
*
p
-v
al
u
e
fo
r
li
n
ea
r
tr
en
d
Cancer Causes Control (2011) 22:1–12 5
123
T
a
b
le
2
In
ta
k
e
o
f
v
it
am
in
s
B
2
an
d
B
6
an
d
C
R
C
ri
sk
st
ra
ti
fi
ed
b
y
g
en
et
ic
st
at
u
s
V
it
am
in
B
2

V
it
am
in
B
6

G
en
e
an
d
S
N
P
(r
s
n
u
m
b
er
,
M
A
F
)*
T
er
ti
le
o
f
in
ta
k
e
C
o
m
m
o
n
h
o
m
o
zy
g
o
te
s
H
et
er
o
zy
g
o
te
s
an
d
ra
re
h
o
m
o
zy
g
o
te
s
C
o
m
m
o
n
h
o
m
o
zy
g
o
te
s
H
et
er
o
zy
g
o
te
s
an
d
ra
re
h
o
m
o
zy
g
o
te
s
n
§
R
R
(9
5
%
C
I)
n
R
R
(9
5
%
C
I)
p
in
te
ra
c
ti
o
n
n
R
R
(9
5
%
C
I)
n
R
R
(9
5
%
C
I)
p
in
te
ra
c
ti
o
n
M
T
H
F
R
c.
6
6
5
C
[
T
(r
s1
8
0
1
1
3
3
,
0
.3
0
)
1
1
0
3
R
ef
.
1
1
7
R
ef
.
0
.7
3
8
1
R
ef
.
1
0
5
R
ef
.
0
.3
2
2
9
2
0
.8
0
(0
.5
4
–
1
.1
7
)
1
1
2
1
.0
2
(0
.7
0
–
1
.4
9
)
9
6
1
.2
4
(0
.8
5
–
1
.8
3
)
1
1
1
1
.1
1
(0
.7
6
–
1
.6
1
)
3
7
8
0
.6
6
(0
.4
2
–
1
.0
4
)
1
0
5
0
.8
9
(0
.5
8
–
1
.3
5
)
9
6
1
.5
0
(0
.9
8
–
2
.2
8
)
1
1
8
1
.0
5
(0
.6
9
–
1
.6
1
)
p
tr
e
n
d
*
*
0
.0
8
0
.5
4
0
.1
2
0
.6
3
M
T
H
F
R
c.
1
2
8
6
A
[
C
(r
s1
8
0
1
1
3
1
,
0
.3
7
)
1
1
0
0
R
ef
.
1
1
8
R
ef
.
0
.4
6
9
0
R
ef
.
9
8
R
ef
.
0
.8
9
2
8
7
0
.7
2
(0
.4
7
–
1
.0
9
)
1
1
6
1
.0
6
(0
.7
5
–
1
.4
9
)
8
7
1
.1
1
(0
.7
4
–
1
.6
6
)
1
1
6
1
.1
6
(0
.8
1
–
1
.6
8
)
3
8
6
0
.7
6
(0
.4
8
–
1
.1
9
)
9
5
0
.8
5
(0
.5
7
–
1
.2
7
)
9
6
1
.1
9
(0
.7
7
–
1
.8
5
)
1
1
5
1
.2
3
(0
.8
2
–
1
.8
5
)
p
tr
e
n
d
0
.2
9
0
.4
2
0
.5
3
0
.3
5
M
T
R
c.
2
7
5
6
A
[
G
(r
s1
8
0
5
0
8
7
,
0
.1
9
)
1
1
3
3
R
ef
.
8
8
R
ef
.
0
.3
4
1
1
5
R
ef
.
7
4
R
ef
.
0
.6
2
2
1
3
7
0
.9
5
(0
.6
8
–
1
.3
1
)
6
8
0
.8
5
(0
.5
4
–
1
.3
4
)
1
4
5
1
.3
3
(0
.9
5
–
1
.8
6
)
6
4
0
.9
1
(0
.5
8
–
1
.4
4
)
3
1
2
7
0
.8
1
(0
.5
6
–
1
.1
7
)
6
1
0
.8
7
(0
.5
3
–
1
.4
4
)
1
3
7
1
.1
7
(0
.8
0
–
1
.7
2
)
7
9
1
.3
1
(0
.8
4
–
2
.0
5
)
p
tr
e
n
d
0
.3
0
0
.5
2
0
.4
9
0
.2
2
M
T
R
R
c.
6
6
A
[
G
(r
s1
8
0
1
3
9
4
,
0
.5
6
)
1
4
9
R
ef
.
1
7
4
R
ef
.
0
.2
6
3
9
R
ef
.
1
5
3
R
ef
.
0
.6
9
2
4
4
0
.7
8
(0
.3
9
–
1
.5
6
)
1
6
2
0
.9
3
(0
.7
0
–
1
.2
5
)
4
3
1
.4
8
(0
.8
0
–
2
.7
4
)
1
6
5
1
.0
3
(0
.7
6
–
1
.3
8
)
3
3
6
0
.5
9
(0
.2
7
–
1
.3
2
)
1
5
3
0
.8
9
(0
.6
5
–
1
.2
3
)
4
7
1
.4
9
(0
.7
4
–
3
.0
0
)
1
7
1
1
.1
1
(0
.8
0
–
1
.5
3
)
p
tr
e
n
d
0
.1
2
0
.5
6
0
.1
9
0
.5
5
D
N
M
T
3
B
C
[
T
(r
s2
4
2
4
9
1
3
,
0
.4
2
)
1
7
9
R
ef
.
1
4
6
R
ef
.
0
.3
9
6
8
R
ef
.
1
2
5
R
ef
.
0
.5
4
2
7
2
1
.0
3
(0
.6
4
–
1
.6
9
)
1
3
5
0
.8
4
(0
.6
1
–
1
.1
5
)
7
1
1
.6
0
(0
.9
6
–
2
.6
7
)
1
3
8
1
.0
4
(0
.7
6
–
1
.4
2
)
3
6
6
1
.0
7
(0
.6
3
–
1
.8
2
)
1
2
3
0
.6
9
(0
.4
8
–
0
.9
9
)
7
8
1
.4
2
(0
.8
5
–
2
.3
7
)
1
4
1
1
.1
8
(0
.8
2
–
1
.7
0
)
p
tr
e
n
d
0
.8
1
0
.0
5
0
.2
1
0
.4
4
D
N
M
T
3
B
C
[
T
(r
s4
0
6
1
9
3
,
0
.1
4
)
1
1
7
1
R
ef
.
5
2
R
ef
.
0
.7
1
1
4
5
R
ef
.
4
5
R
ef
.
0
.3
9
2
1
5
1
0
.8
6
(0
.6
3
–
1
.1
7
)
5
3
0
.8
6
(0
.5
0
–
1
.4
8
)
1
6
3
1
.1
2
(0
.8
3
–
1
.5
2
)
4
5
1
.2
8
(0
.7
0
–
1
.3
6
)
3
1
4
6
0
.8
4
(0
.5
9
–
1
.1
9
)
4
3
0
.6
6
(0
.3
7
–
1
.1
9
)
1
6
0
1
.1
2
(0
.8
0
–
1
.5
8
)
5
8
1
.9
0
(1
.0
0
–
3
.6
0
)
p
tr
e
n
d
0
.3
3
0
.2
0
0
.6
0
0
.0
4
E
H
M
T
1
G
[
A
(r
s4
6
3
4
7
3
6
,
0
.1
0
)
1
1
8
0
R
ef
.
4
2
R
ef
.
0
.7
4
1
6
1
R
ef
.
3
0
R
ef
.
0
.7
0
2
1
6
5
0
.9
3
(0
.6
9
–
1
.2
5
)
4
0
0
.9
4
(0
.4
9
–
1
.8
2
)
1
6
9
1
.0
7
(0
.8
0
–
1
.4
4
)
3
8
1
.3
3
(0
.6
8
–
2
.5
8
)
3
1
5
7
0
.8
5
(0
.6
2
–
1
.1
8
)
3
0
0
.6
9
(0
.3
2
–
1
.5
0
)
1
7
2
1
.1
5
(0
.8
4
–
1
.5
8
)
4
4
1
.5
2
(0
.7
1
–
3
.2
6
)
p
tr
e
n
d
0
.3
8
0
.3
8
0
.4
0
0
.2
9
E
H
M
T
2
G
[
A
(r
s5
3
5
5
8
6
,
0
.3
5
)
1
9
8
R
ef
.
1
2
5
R
ef
.
0
.6
6
8
1
R
ef
.
1
0
8
R
ef
.
0
.6
6
2
8
8
0
.9
3
(0
.6
2
–
2
.3
8
)
1
1
6
0
.8
5
(0
.5
9
–
1
.2
1
)
8
5
0
.9
8
(0
.6
5
–
1
.4
8
)
1
2
3
1
.2
5
(0
.8
8
–
1
.7
8
)
3
7
9
0
.8
5
(0
.5
4
–
1
.3
4
)
1
0
5
0
.7
5
(0
.5
0
–
1
.1
2
)
9
9
1
.1
7
(0
.7
5
–
1
.8
3
)
1
1
5
1
.2
5
(0
.8
5
–
1
.8
6
)
p
tr
e
n
d
0
.5
3
0
.2
1
0
.4
5
0
.3
0
6 Cancer Causes Control (2011) 22:1–12
123
optimal MTHFR activity in individuals homozygous for
the common c.665CC (rs1801133) variant, with common
PRDM2 GG (rs2235515) genotype and among those with
the variant allele of DNMT3B C [ T (rs2424913). We
observed a strong inverse association between vitamin B2
intake and CRC risk among individuals carrying B 1 rare
allele in the combination of any of the folate metabolizing
enzymes MTHFR, MTR, or MTRR. There were no asso-
ciations with the CIMP phenotype overall, or within strata
of the studied genotypes.
The MTHFR c.665C [ T (rs1801133) polymorphism
reduces binding of the MTHFR enzyme to its cofactor flavin
adenine dinucleotide (FAD), a metabolite of vitamin B2,
resulting in loss of enzymatic activity [15]. The potentially
resulting reduced bioavailability of methyl groups may
induce DNA hypomethylation in for example blood cells
[35, 36] or CpG island promoter hypermethylation in CRC
[19, 37]. We observed an inverse association between vita-
min B2 and CRC risk, predominantly among subjects
homozygous for the MTHFR c.665CC (rs1801133) variant,
suggesting that vitamin B2 may maximize the catalytic
activity of MTHFR when binding to FAD is optimal. Simi-
larly, it was recently observed that high vitamin B2 plasma
concentrations, in combination with MTHFR c.665CC or CT
genotypes, may reduce risk of CRA recurrence, whereas
such an inverse association was not observed among indi-
viduals with the MTHFR c.665TT variant [38].
The rare variant of another MTHFR polymorphism,
MTHFR c.1286A [ C (rs1801131), may also reduce enzy-
matic MTHFR activity [16], and was associated with CIMP
in colorectal cancer [18], possibly in combination with low
folate and methionine intakes and high alcohol consump-
tion [17]. However, we previously observed that this
polymorphism was neither associated with overall CRC or
with the CIMP phenotype [39], nor when methyl donor
intake was accounted for in the current study. Possibly, the
use of different panels to identify CIMP-high (a ‘‘classic’’
panel [17] or a new panel [18, 39] which may be more
robust [2]) may have contributed to this inconsistency.
Moreover, different essays to measure DNA methylation
were used, i.e. MSP [17, 39] or a quantitative method [18].
However, in addition to this variety of approaches, it is also
important to realize that the one-carbon metabolism is
involved in both DNA synthesis as well as DNA methyla-
tion, both of which may have an effect on colorectal
carcinogenesis [40]. The relative contribution of each of
these biological processes in carcinogenesis remains to be
established and may not have been similar in the investi-
gated study populations. Furthermore, global DNA hy-
pomethylation and CIMP are possibly inversely associated
in CRC [41], and methyl group donors may have an effect
on both of these potentially distinct methylation-associated
pathways in colorectal carcinogenesis. In this respect, lowT
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folate and high alcohol intakes were associated with LINE-
1 hypomethylation as an indicator for global DNA hy-
pomethylation [8], which is in agreement with in vivo
experimental data [7].
We did not observe associations between methyl donor
intake and the CIMP phenotype in CRC, either overall or
after stratifying the analyses for the genetic variants of
folate metabolizing enzymes or methyltransferases.
Table 3 Dietary folate, methionine, vitamins B2 and B6 and CRC risk for combinations of genotypes DNA methyltransferase 3B
DNA methyltransferase 3B
Tertile
of intake
0* 1 2 p-value for
interaction
n RR (95% CI) n RR (95% CI) n RR (95% CI)
Folate 1 53 Ref. 151 Ref. 22 Ref. 0.48
2 37 0.72 (0.39–1.35) 107 0.63 (0.45–0.89) 20 0.67 (0.27–1.67)
3 39 0.76 (0.39–1.48) 163 1.10 (0.78–1.55) 23 0.78 (0.31–1.93)
ptrend 0.37 0.54 0.79
Methionine 1 53 Ref. 137 Ref. 20 Ref. 0.07
2 37 0.74 (0.37–1.47) 142 1.18 (0.85–1.63) 24 1.71 (0.77–3.79)
3 39 0.44 (0.21–0.94) 142 1.12 (0.79–1.60) 21 1.48 (0.56–3.90)
ptrend 0.05 0.66 0.47
Vitamin B2 1 47 Ref. 154 Ref. 22 Ref. 0.87
2 41 1.09 (0.56–2.12) 137 0.78 (0.57–1.08) 25 1.30 (0.57–2.98)
3 41 1.52 (0.71–3.22) 130 0.72 (0.50–1.05) 18 0.79 (0.29–1.74)
ptrend 0.36 0.10 0.41
Vitamin B6 1 42 Ref. 127 Ref. 21 Ref. 0.29
2 42 1.80 (0.88–3.70) 147 1.13 (0.83–1.54) 18 0.98 (0.37–2.57)
3 45 1.37 (0.68–2.75) 147 1.15 (0.81–1.63) 26 2.12 (0.79–5.72)
ptrend 0.44 0.46 0.18
* Number of variant alleles (i.e. heterozygotes or homozygotes for the rare allele)
Table 4 Dietary folate, methionine, vitamins B2 and B6 and CRC risk for combinations of genotypes in folate metabolizing enzymes
Folate metabolizing enzymes
Tertile
of intake
B1* 2 C3 p-value for
interaction
n RR (95% CI) n RR (95% CI) n RR (95% CI)
Folate 1 41 Ref. 95 Ref. 83 Ref. 0.99
2 32 0.52 (0.24–1.14) 66 0.56 (0.37–0.86) 61 0.76 (0.44–1.31)
3 42 1.23 (0.58–2.63) 102 0.91 (0.60–1.40) 75 0.89 (0.51–1.54)
ptrend 0.51 0.97 0.66
Methionine 1 40 Ref. 85 Ref. 81 Ref. 0.38
2 41 1.50 (0.70–3.21) 89 1.24 (0.82–1.90) 70 0.73 (0.44–1.21)
3 34 0.99 (0.38–2.53) 89 1.06 (0.68–1.65) 68 0.70 (0.40–1.24)
ptrend 0.90 0.90 0.18
Vitamin B2 1 43 Ref. 91 Ref. 83 Ref. 0.36
2 40 0.76 (0.37–1.54) 90 0.95 (0.63–1.43) 71 0.94 (0.58–1.53)
3 32 0.30 (0.11–0.81) 82 0.88 (0.55–1.39) 65 1.05 (0.61–1.80)
ptrend 0.005 0.96 0.87
Vitamin B6 1 31 Ref. 83 Ref. 71 Ref. 0.82
2 46 0.94 (0.94–4.03) 88 1.05 (0.70–1.56) 69 1.07 (0.63–1.80)
3 38 2.32 (1.00–5.36) 92 1.06 (0.68–1.65) 79 1.39 (0.80–2.42)
ptrend 0.07 1.00 0.21
* Number of variant alleles (i.e. heterozygotes or homozygotes for the rare allele)
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Moreover, overall associations between methyl donor
intake and CIMP in CRC were not observed in another
population-based study [11], while in the same cohort, a
diet-gene association with CIMP in CRC was observed for
only one out of thirteen one-carbon metabolism genes [17].
However, these studies, as well as our study, may have
lacked adequate power to demonstrate such associations.
The effect of methyl donor intake on gene promoter hy-
permethylation may indeed be weak though, and to dem-
onstrate whether such an effect is modified by genetic
variability of the methyl metabolism requires studies with
large numbers of cases. Nonetheless, we did observe an
inverse association between vitamin B2 and CRC risk in
individuals carrying B1 variant allele out of the four
studied SNPs of folate metabolizing enzymes, suggesting
that the combination of common wild-type genotypes,
which possibly results in higher bioavailability of methyl
groups, protects against CRC in these people.
The findings of our study may indicate that relatively
high methionine intake protects against CRC if enzymatic
DNMT3B activity is not affected by two polymorphisms.
DNMT3B activity, which may be increased by the
DNMT3B C [ T (rs2424913) polymorphism [42], was
associated with CIMP-high in CRC [43], and with increased
risk of various other types of cancer [42, 44, 45]. In addi-
tion, experimental research suggested that DNMT3B
overexpression induced formation of tumors with promoter
hypermethylation [46]. DNMT3B C [ T (rs2424913) was
also associated with increased colorectal adenoma risk in
individuals with low folate and methionine intakes [47],
suggesting a nutrient–gene interaction in colorectal carci-
nogenesis. In view of the function of the DNMT3B enzyme
of incorporating methyl groups into DNA, an interaction
between methionine intake, DNMT3B polymorphisms and
CpG island hypermethylation may be expected, but we did
not observe clear associations between methyl donor intake
and CIMP, MLH1 hypermethylation or MSI when
accounting for DNMT3B genotypes.
The potential protective effects of vitamin B2 or methi-
onine may only be present among individuals with B1
polymorphism in folate metabolizing enzymes or among
those with common wild-type genotypes of DNMT3B,
respectively. This suggests that the occurrence of only one
rare variant may be compensated for, but that the combi-
nation of several polymorphic genes may lead to disruption
of a particular metabolic or regulatory function and to the
abolishment of beneficial effects of nutrients. However, we
should be careful in drawing definite conclusions because
the sample size of our study may have been insufficient to
conduct stratified analyses with adequate precision. More-
over, the P-values for interaction were not statistically
significant, suggesting the absence of heterogeneity of diet
associations with CRC across genotypes. In addition, we
conducted several stratified analyses, and these multiple
comparisons do not exclude the possibility of reporting
chance findings. Nonetheless, although these observations
Table 5 Dietary folate, methionine, vitamins B2 and B6 and CRC risk for combinations of genotypes in histone methyltransferases
Histone methyltransferases
Tertile
of intake
0* 1 C2 p-value for
interaction
n RR (95% CI) n RR (95% CI) n RR (95% CI)
Folate 1 43 Ref. 103 Ref. 72 Ref. 0.76
2 30 0.47 (0.24–0.90) 76 0.72 (0.47–1.10) 51 0.71 (0.43–1.17)
3 44 0.91 (0.46–1.80) 90 0.92 (0.61–1.39) 78 1.11 (0.67–1.85)
ptrend 0.64 0.69 0.65
Methionine 1 41 Ref. 93 Ref. 68 Ref. 0.61
2 35 1.03 (0.51–2.06) 89 1.08 (0.71–1.64) 70 1.12 (0.68–1.85)
3 41 1.14 (0.58–2.23) 87 1.12 (0.71–1.76) 63 0.77 (0.44–1.35)
ptrend 0.80 0.76 0.34
Vitamin B2 1 45 Ref. 96 Ref. 75 Ref. 0.99
2 37 0.71 (0.37–1.37) 94 0.94 (0.63–1.40) 64 0.81 (0.50–1.30)
3 35 0.55 (0.26–1.13) 79 0.86 (0.54–1.37) 62 0.78 (0.47–1.31)
ptrend 0.22 0.45 0.49
Vitamin B6 1 36 Ref. 85 Ref. 60 Ref. 0.29
2 29 0.85 (0.44–1.64) 100 1.38 (0.94–2.04) 73 1.11 (0.68–1.79)
3 52 1.69 (0.79–3.60) 84 1.01 (0.66–1.55) 68 1.39 (0.81–2.39)
ptrend 0.10 0.93 0.34
* Number of variant alleles (i.e. heterozygotes or homozygotes for the rare allele)
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are based on subgroup analyses, and thus have to be inter-
preted with some caution, this study may indicate that
combining genotypes is important to reveal associations of
dietary factors with cancer risk. Such an approach has not
been followed in previous studies investigating associations
between genetic factors and cancer risk, and we recommend
that combinations of genotypes should be considered in
addition to overall analyses in future studies.
Subgroup analyses in the present study indicated that
vitamin B2 and methionine may protect against CRC
among individuals who do not carry rare variants of folate
metabolizing enzymes and a DNA methyltransferase.
However, larger studies are needed to investigate a
potential interaction between dietary methyl donor intake,
genetic variation of folate metabolizing enzymes and epi-
genetic regulators, and methylation endpoints in CRC with
more precision. Because multiple genes may collectively
affect the folate metabolism, combining genotypes of
related genes is a useful approach of investigating associ-
ations of dietary methyl donors and CRC.
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